Table 2 Demographic and clinical features of APS patients with and without CNS manifestations.
|  | With CNS manifestations (n = 119) | Without CNS manifestations (n = 223) | P |
|---|---|---|---|
Age at diagnosis (years) | 49.7 ± 16.1 | 41.2 ± 15.7 |  < 0.001 |
Male gender, n (%) | 33 (27.7) | 43 (19.1) | 0.073 |
Disease duration (months) | 10 (1, 48) | 7 (1, 36) | 0.033 |
Secondary APS, n (%) | 75 (63.0) | 90 (40.0) |  < 0.001 |
Extracranial arterial events, n (%) | 52 (43.7) | 72 (32.3) | 0.037 |
Venous events, n (%) | 49 (41.2) | 85 (38.1) | 0.638 |
Obstetric events, n (%) | 25 (21.0) | 104 (46.2) |  < 0.001 |
Livedo reticularis, n (%) | 9 (7.6) | 5 (2.2) | 0.023 |
Diffuse alveolar hemorrhage, n (%) | 1 (0.8) | 0 (0) | 1.000 |
APS nephropathy, n (%) | 3 (2.5) | 2 (0.9) | 0.347 |
Thrombocytopenia, n (%) | 46 (38.7) | 58 (26.0) | 0.015 |
Diabetes, n (%) | 27 (22.7) | 20 (8.9) |  < 0.001 |
Hypertension, n (%) | 54 (45.4) | 51 (22.7) |  < 0.001 |
Dyslipidaemia, n (%) | 89 (74.8) | 29 (12.9) |  < 0.001 |
Smoking, n (%) | 22 (18.5) | 30 (13.3) | 0.217 |
Obesity, n (%) | 10 (8.4) | 23 (10.3) | 0.569 |
aβ2GPI, n (%) | 75 (63) | 161 (71.6) | 0.081 |
aCL, n (%) | 90 (75.6) | 149 (66.2) | 0.091 |
LA, n (%) | 88 (73.9) | 141 (62.7) | 0.045 |
Triple aPL positivity, n (%) | 46 (38.7) | 76 (34.1) | 0.400 |
Antiplatelet drugs, n (%) | 46 (38.7) | 82 (36.4) | 0.732 |
Anticoagulants, n (%) | 53 (44.5) | 148 (65.8) |  < 0.001 |
Corticosteroids, n (%) | 99 (83.2) | 155 (68.9) | 0.006 |
Hydroxychloroquine, n (%) | 60 (50.4) | 167 (74.2) |  < 0.001 |
Immunosuppressants, n (%) | 102 (85.7) | 193 (86.5) | 0.831 |
Statins, n (%) | 15 (12.6) | 131 (58.2) |  < 0.001 |
